Terazosin Suppresses Endometriosis Progression via Downregulation of Steroidogenic Factor-1: An Experimental Rat Model

Ahmet Beyazıt
2026 · doi:10.17632/c2ybb3kzdf · W7143488909
Lab / animal OA: green CC0
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-08-27 ⓘ

This in vivo study evaluated the therapeutic efficacy of terazosin, an alpha-1 adrenergic receptor antagonist, in a surgically induced rat model of endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-10 · read from full text ⓘ

This experimental study evaluated the therapeutic efficacy of terazosin, an alpha-1 adrenergic receptor antagonist, using a surgically induced rat model of endometriosis. The researchers analyzed raw biochemical and molecular data to determine how the drug influenced disease progression in the animal subjects. Key findings indicated that terazosin suppressed endometriosis progression by downregulating the expression of steroidogenic factor-1. This paper is centrally about endometriosis — specifically investigating the molecular mechanism by which terazosin inhibits lesion growth via SF-1 downregulation in an experimental setting.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

This dataset contains the raw biochemical, molecular, data and statistics from an in vivo experimental study evaluating the therapeutic efficacy of terazosin, an alpha-1 adrenergic receptor antagonist, in a surgically induced rat model of endometriosis.
Full text 506 characters · extracted from oa-html · click to expand
Terazosin Suppresses Endometriosis Progression via Downregulation of Steroidogenic Factor-1: An Experimental Rat Model Published: 30 March 2026| Version 1 | DOI: 10.17632/c2ybb3kzdf.1 Contributor: Ahmet BeyazitDescription This dataset contains the raw biochemical, molecular, data and statistics from an in vivo experimental study evaluating the therapeutic efficacy of terazosin, an alpha-1 adrenergic receptor antagonist, in a surgically induced rat model of endometriosis. Files Categories Endometriosis

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

openalex
last seen: 2026-06-29T06:01:59.144155+00:00
License: CC0 · commercial use OK